Geode Capital Management
BBOT

Geode Capital Management’s BridgeBio Oncology BBOT Stock Holding History

Geode Capital Management’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.74M Buy
622,351
+43,117
+7% +$360K ﹤0.01% 2944
2026
Q1 		$5.19M Buy
579,234
+17,247
+3% +$185K ﹤0.01% 2713
2025
Q4 		$7.04M Buy
561,987
+20,385
+4% +$247K ﹤0.01% 2579
2025
Q3 		$6.27M Buy
541,602
+528,274
+3,964% +$5.5M ﹤0.01% 2667
2025
Q2 		$142K Buy
13,328
+54
+0.4% +$584 ﹤0.01% 3973
2025
Q1 		$150K Hold
13,274
– – ﹤0.01% 3927
2024
Q4 		$139K Buy
13,274
+2,405
+22% +$25.3K ﹤0.01% 4003
2024
Q3 		$114K Hold
10,869
– – ﹤0.01% 4069
2024
Q2 		$111K Hold
10,869
– – ﹤0.01% 4110
2024
Q1 		$112K Buy
+10,869
New +$113K ﹤0.01% 4128

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management's BBOT Position: Q2 2026 in Review

Geode Capital Management increased its BridgeBio Oncology (BBOT) stake by 7.4% in Q2 2026, buying an estimated $360K and bringing the position to 622,351 shares worth $4.74M. The position accounts for ﹤0.01% of the portfolio, ranked #2944.

Geode Capital Management first reported a position in BBOT in Q1 2024 and has held it in 10 quarters since. The position peaked at $7.04M in Q4 2025. 57 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Geode Capital Management held 622,351 shares of BridgeBio Oncology worth $4.74M as of Q2 2026.
  • Geode Capital Management bought 43,117 BridgeBio Oncology shares in Q2 2026, an estimated $360K.
  • BridgeBio Oncology made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2944 holding.
  • Geode Capital Management first reported a position in BridgeBio Oncology in Q1 2024 and has held it in 10 quarters since.
  • Geode Capital Management's BridgeBio Oncology position peaked at $7.04M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.